We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience. You can read our Cookie Policy here.

Advertisement
UK-Norwegian Collaboration Aims to Develop a New Living Skin Equivalent Model
News

UK-Norwegian Collaboration Aims to Develop a New Living Skin Equivalent Model

UK-Norwegian Collaboration Aims to Develop a New Living Skin Equivalent Model
News

UK-Norwegian Collaboration Aims to Develop a New Living Skin Equivalent Model

Read time:
 

Want a FREE PDF version of This News Story?

Complete the form below and we will email you a PDF version of "UK-Norwegian Collaboration Aims to Develop a New Living Skin Equivalent Model"

First Name*
Last Name*
Email Address*
Country*
Company Type*
Job Function*
Would you like to receive further email communication from Technology Networks?

Technology Networks Ltd. needs the contact information you provide to us to contact you about our products and services. You may unsubscribe from these communications at any time. For information on how to unsubscribe, as well as our privacy practices and commitment to protecting your privacy, check out our Privacy Policy

Epistem and ScandiDerma have announced that they aim to develop a new in vitro human living skin equivalent model for testing inflammatory responses.

This is a novel method that will add to the field of dermatological testing as a whole and help create more activity in extracting high value compounds from biomass.

The collaboration is made possible through the UK's innovation agency, the Technology Strategy Board, and Innovation Norway following a successful application for funding in the "Sustainable high value chemical manufacture through industrial biotechnology" competition.

Matthew Walls, Epistem CEO commented "The collaboration with ScandiDerma presents an exciting opportunity to leverage Epistem's strong scientific background in skin biology and inflammation to address the shortage of robust human dermatology models for testing inflammatory responses.

"For ScandiDerma this is an important milestone in building up our competence around test-systems and how to rapidly determine good lead candidates from our bioprospecting activities" Ingebjorg Pernille Nedal, CEO ScandiDerma.

The project will last from May 2013 to March 2014 and will run from the project leader Epistem's facilities in Manchester UK and ScandiDerma's facilities in Barents Biocenter, Tromso, Norway.

Advertisement